+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07283731

Evaluation of Zanzalintinib Combined with Pembrolizumab for Advanced or Metastatic Soft-Tissue Sarcoma Subtypes

Led by M.D. Anderson Cancer Center · Updated on 2026-11-02

20

Participants Needed

1

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating if the combination of zanzalintinib and pembrolizumab can help control select subtypes of advanced or metastatic soft-tissue sarcoma, including undifferentiated pleomorphic sarcoma UPS, myxofibrosarcoma MFS, high grade pleomorphic sarcoma HGPS, and high grade undifferentiated sarcoma HGUS. This phase 2 trial aims to estimate progression-free survival, overall response rate, and the safety profile of these treatments in affected adults. Participants receive both zanzalintinib orally and pembrolizumab intravenously. The study follows a single treatment group design where all participants receive this combination. Treatment schedules and dosing details are guided by clinical criteria, and the study monitors participants through an average of one year to observe treatment effects and safety. During the study, participants are closely assessed through imaging and clinical exams to measure disease progression and response based on RECIST v1.1 criteria. Safety is monitored by tracking adverse events using CTCAE v5 standards. Laboratory tests, biopsies, and evaluations of organ function help ensure participants health during treatment. The study also involves ongoing follow-up to evaluate progression-free survival and adverse events until study completion.

CONDITIONS

Brief Title

Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma

Research Team

M

Michael S Nakazawa, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here